Table 1. Patient baseline characteristics.

Characteristic, n (% unless otherwise stated)	DI (n=42)a	DF (n=43)a	Total (n=85)
Male	35 (83.3)	35 (81.4)	70 (82.4)
Race
Caucasian	40 (95.2)	42 (97.7)	82 (96.5)
Other	2 (4.8)	1 (2.3)	3 (3.5)
Age
<65 years	26 (61.9)	31 (72.1)	57 (67.1)
⩾65 years	16 (38.1)	12 (27.9)	28 (32.9)
Median age (range), years	62 (40–76)	60 (38–74)	61 (38–76)
KPS before first infusion
⩾90	24 (57.1)	20 (46.5)	44 (51.8)
100	7 (16.7)	9 (20.9)	16 (18.8)
90	17 (40.5)	11 (25.6)	28 (32.9)
80	12 (28.6)	11 (25.6)	23 (27.1)
70	6 (14.3)	12 (27.9)	18 (21.2)
Median KPS (range) score	90 (70–100)	80 (70–100)	90 (70–100)
Weight loss in prior 3 months
⩽5%	12 (28.6)	14 (32.6)	26 (30.6)
>5%–⩽10%	16 (38.1)	10 (23.3)	26 (30.6)
>10%	14 (33.3)	19 (44.2)	33 (38.8)
Median (range) weight loss in prior 3 months, %	9 (0–25)	10 (0–30)	10 (0–30)
Primary tumour site
Distal (antrum+body)	27 (64.3)	19 (44.2)	46 (54.1)
Proximal (oesophagogastric junction, fundus)	15 (35.7)	24 (55.8)	39 (45.9)
Disease status
Metastatic	40 (95.2)	40 (93.0)	80 (94.1)
Locally advanced	2 (4.8)	3 (7.0)	5 (5.9)
Histology
Adenocarcinoma	40 (95.2)	40 (93.0)	80 (94.1)
Linitis plastica	2 (4.8)	3 (7.0)	5 (5.9)
Number of organs involved
1	8 (19.0)	12 (27.9)	20 (23.5)
2	18 (42.9)	16 (37.2)	34 (40.0)
⩾3	16 (38.1)	15 (34.9)	31 (36.5)
Prior therapies
Radiotherapy	—	—	—
Chemotherapy (adjuvant/neoadjuvant)	2 (4.8)	1 (2.3)	3 (3.5)
Surgery	16 (38.1)	15 (34.9)	31 (36.5)
Curative intent	9 (21.4)	11 (25.6)	20 (23.5)
Palliative	7 (16.7)	4 (9.3)	11 (12.9)

Abbreviations: DF=docetaxel and 5-fluorouracil; DI=docetaxel and irinotecan; ITT=intention-to-treat; KPS=Karnofsky performance status.

^aITT population.